T2 Biosystems, a company developing direct detection products enabling
superior diagnostics, today announced the presentation of new data on
hemostasis monitoring at the American Association for Clinical Chemistry
Annual Meeting, July 15-19, 2012, in Los Angeles, CA. T2Hemostasis is
the first platform capable of rapidly characterizing key coagulation,
platelet and other hematologic factors directly from whole blood on a
single, compact instrument. The data presented at AACC demonstrate that
T2Hemostasis provides reliable and rapid results when compared to
conventional systems.
"T2Hemostasis, which utilizes the company's proprietary T2MR detector,
is able to monitor several key hemostasis measurements, including
clotting time, platelet activity, fibrinolysis and hematocrit, on a
single assay in minutes," said John McDonough, CEO, T2 Biosystems. "T2
Bio's approach could enable more effective decisions for anticoagulation
and anti-platelet therapies, as well as the selection of appropriate
transfusion products during cardiovascular procedures. The benefits of
improved hemostasis monitoring and therapeutic decision-making have a
tremendous potential impact on the cost and quality of healthcare."